- Home
- CDE vs MDGL Comparison
CDE vs MDGL Comparison
Compare CDE & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDE | MDGL |
|---|---|---|
| Founded | 1928 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 9.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CDE | MDGL |
|---|---|---|
| Price | $15.90 | $577.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $16.33 | ★ $543.33 |
| AVG Volume (30 Days) | ★ 16.7M | 340.6K |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $1,700,723,000.00 | $740,640,000.00 |
| Revenue This Year | $95.35 | $436.04 |
| Revenue Next Year | $35.11 | $53.17 |
| P/E Ratio | $21.49 | ★ N/A |
| Revenue Growth | 68.28 | ★ 864.21 |
| 52 Week Low | $4.58 | $265.00 |
| 52 Week High | $23.62 | $605.00 |
Technical Indicators
Market Signals| Indicator | CDE | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 63.95 |
| Support Level | $15.65 | $569.04 |
| Resistance Level | $17.88 | $594.27 |
| Average True Range (ATR) | 0.85 | 26.23 |
| MACD | 0.25 | -2.03 |
| Stochastic Oscillator | 54.16 | 67.29 |
Price Performance
Historical ComparisonAbout CDE Coeur Mining Inc.
Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada, and Mexico.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.